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HIV-1 Env protein functions in the entry process and is the target of neutralizing
antibodies. Its intrinsically high mutation rate is certainly one of driving forces for
persistence/survival in hosts. For optimal replication in various environments, HIV-1
Env must continue to adapt and evolve through balancing sometimes incompatible
function, replication fitness, and neutralization sensitivity. We have previously reported
that adapted viruses emerge in repeated and prolonged cultures of cells originally
infected with a macaque-tropic HIV-1NL4−3 derivative. We have also shown that the
adapted viral clones exhibit enhanced growth potentials both in macaque PBMCs and
individuals, and that three single-amino acid mutations are present in their Env V1/C2/C4
domains. In this study, we investigated how lab-adapted and highly neutralization-
sensitive HIV-1NL4−3 adapts its Env to macaque cells with strongly replication-restrictive
nature for HIV-1. While a single and two mutations gave a significantly enhanced
replication phenotype in a macaque cell line and also in human cell lines that stably
express either human CD4 or macaque CD4, the virus simultaneously carrying the three
adaptive mutations always grew best. Entry kinetics of parental and triple mutant viruses
were similar, whereas the mutant was significantly more readily inhibited for its infectivity
by soluble CD4 than parental virus. Furthermore, molecular dynamics simulations of
the Env ectodomain (gp120 and gp41 ectodomain) bound with CD4 suggest that the
three mutations increase binding affinity of Env for CD4 in solution. Thus, it is quite
likely that the affinity for CD4 of the mutant Env is enhanced relative to the parental
Env. Neutralization sensitivity of the triple mutant to CD4 binding site antibodies was
not significantly different from that of parental virus, whereas the mutant exhibited
a considerably higher resistance against neutralization by a CD4-induced epitope
antibody and Env trimer-targeting V1/V2 antibodies. These results suggest that the three
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adaptive mutations cooperatively promote viral growth via increased CD4 affinity, and
also that they enhance viral resistance to several neutralization antibodies by changing
the Env-trimer conformation. In total, we have verified here an HIV-1 adaptation pathway
in host cells and individuals involving Env derived from a lab-adapted and highly
neutralization-sensitive clone.
Keywords: HIV-1, Env, adaptive mutation, CD4, replication potential, neutralization sensitivity, Env structure
INTRODUCTION
HIV-1 Env protein consists of gp120 and gp41, which are
cleaved and matured products of the gp160 precursor protein
(Freed and Martin, 1995, 2013; Clapham and McKnight, 2002;
Wilen et al., 2012). Gp120 is a surface protein of Env,
and contains discontinuous conserved (C1–C5) and variable
regions (V1–V5), whereas gp41 has several functional domains
including fusion peptide, ectodomain, transmembrane domain,
and cytoplasmic tail. HIV-1 Env works as a trimer of a
gp120-gp41 heterodimer molecule on viral entry into host
target cells. HIV-1 entry process is initiated by attachment
of gp120 to cellular receptor CD4. Upon its binding, gp120
experiences structural rearrangements required for interaction
with cellular co-receptor, CCR5 and/or CXCR4. Binding of
gp120 to the co-receptor triggers large conformational changes
of gp41, and thereby induces virus-cell membrane fusion.
As such, successful viral entry into cells is achieved by
continuous changes in the conformation of gp120 and gp41
proteins, and is critical for efficient viral replication. In addition
to functions in the entry process, Env is also targeted by
neutralizing antibodies (NAbs), because it is the only viral
protein expressed on virion surface. NAbs are categorized by
defining an epitope or epitope cluster on Env: CD4 binding
site (CD4bs), CD4-induced epitope (CD4i), V1/V2, Glycan-
V3, silent face center, fusion peptide, subunit interface, and
membrane-proximal external region (Benjelloun et al., 2012;
Kwong and Mascola, 2018). To escape binding to NAbs
and maintain optimal replication level, HIV-1 Env possesses
high ability to mutate and adapt to various surrounding
environments. On one hand, mutations in HIV-1 Env can
affect both replication capability and neutralization susceptibility:
a decrease in replication fitness by a mutation conferring
resistance to NAbs; an increase in neutralization sensitivity by
a growth-enhancing mutation. Thus, in the adaptation process,
it is biologically important for HIV-1 Env to appropriately
balance the efficient viral entry via interaction with receptor/co-
receptors and the escape from recognition of NAbs by masking
epitopes.
Virus adaptation studies have provided a large amount of
useful information on viral replicative cycle through extensive
analyses of newly emerged mutations in viral genome and their
functional and structural effects on viral proteins. For HIV-1,
in vitro adaptation experiments have revealed various mutants
with phenotypes characteristic of viruses resulted from selection
pressures, such as antiviral drugs, restriction factors, or limited
expression of viral receptor/co-receptors (Trkola et al., 2002;
Kuhmann et al., 2004; Pacheco et al., 2008, 2010; Yoshimura
et al., 2014; Garg et al., 2016). However, the adaptation of HIV-1
primary isolates to T-cell lines or peripheral blood mononuclear
cells (PBMCs) generally and specifically led to better-growing
variants with an enhanced sensitivity to soluble CD4 (sCD4)
and several NAbs (Moore and Ho, 1995; Wrin et al., 1995;
Clapham and McKnight, 2002; Pugach et al., 2004). In addition,
while adapting HIV-1 primary isolates to cells with a low CD4
expression (CD4low cells) resulted in an increase in viral CD4-
binding ability and in viral infectivity for CD4low target cells
including macrophages, these changes were accompanied by a
reduced infectivity in CD4high T-cells and by an augmented
sensitivity to NAbs (Beauparlant et al., 2017). On one hand,
it has been shown that Env proteins from circulating HIV-
1 strains have a reduced binding capacity to macaque CD4.
An SIV/HIV-1 chimeric virus (SHIV) with a circulating HIV-
1 env gene showed enhanced macaque CD4-mediated entry
following adaptation to macaque cells by acquiring amino
acid changes in Env, but its sensitivity to several NAbs was
concomitantly increased (Humes and Overbaugh, 2011; Humes
et al., 2012; Boyd et al., 2015). Although adaptation pathways
seemed to vary depending on virus strains and host environments
used in the experiments (van Opijnen et al., 2007), virus
affinity to sCD4 and virus sensitivity to several NAbs tend to
increase through growth adaptation of primary HIV-1 in cell
cultures.
We have previously demonstrated that macaque-tropic
HIV-1 derivatives (HIV-1mt), which carry minimal portions
of SIVmacMA239 genome, can variously and successfully
adapt to different macaque cell lines (Kamada et al., 2006;
Nomaguchi et al., 2008, 2013a,c, 2014; Yokoyama et al., 2016).
This experimental system composed of HIV-1mt clones and
macaque cell lines serves for a model study to understand
how HIV-1 mutates and adapts to replication-restrictive
environments. Our prototype HIV-1mt clone designated ScaVR,
which was constructed from a lab-adapted and neutralization-
sensitive HIV-1NL4−3 strain, replicated poorly in macaque
cells (Kamada et al., 2006). In attempts to increase viral
replication efficiency, we repeatedly performed prolonged
cultivations of macaque cells infected with various HIV-1mt
clones. First, we successfully obtained an adapted (growth-
enhanced) clone of ScaVR designated NL-DT5R (5R) (Kamada
et al., 2006). The 5R genome contained two synonymous
mutations [one in long terminal repeat (LTR) and another
in pol-protease region], and two non-synonymous mutations
in env. Then, the other adapted viruses were obtained
through long-term cultures of macaque cells infected with 5R
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(Nomaguchi et al., 2008, 2013a). Of several mutations identified
in their genomes, only two non-synonymous mutations (one
in pol-integrase and another in env regions) actually promoted
viral replication potential. Importantly, the enhancement of
viral replication efficiency in macaque cells was indeed reflected
in viral growth ability in macaque individuals (Igarashi
et al., 2007; Saito et al., 2011). These results indicated that
the adaptive mutations identified in cell cultures certainly
contribute to promotion of viral growth in individuals. In
this work, we studied functional and structural bases for
viral growth enhancement by the three Env mutations that
spontaneously emerged during repeated in vitro adaptation
processes. We aimed to clarify how a highly neutralization-
sensitive virus clone adapts to a replication-restrictive condition




A prototype HIV-1mt clone, ScaVR (Kamada et al., 2006), was
used as a parental clone in this study. Introduction of mutations
into env gene was carried out by site-directed mutagenesis with
Pfu DNA polymerase (Agilent Technologies). Human CD4 and
cynomolgus (CyM) CD4 coding sequences were amplified by
PCR using cDNAs synthesized from a human T-cell line H9
and a CyM lymphocyte line HSC-F, respectively. Amplified
human- and CyM-CD4 DNA fragments were cloned into the
NotI site in pCEP4 vector (Thermo Fisher Scientific Inc.),
and resultant clones were named H9-CD4+pCEP4 and HSCF-
CD4+pCEP4, respectively. Amino acid sequence of CD4 derived
from H9 cells was different from that of human CD4 (GenBank
accession number AAB51309) at amino acid position 176 (L
to F). Amino acid sequence of CD4 from HSC-F cells was
identical to that of CyM CD4 (GenBank accession number
EHH66018).
Cells
A human embryonic kidney cell line 293T (Lebkowski et al.,
1985) and a reporter cell line, TZM-bl carrying a luciferase
gene driven by viral LTR (Platt et al., 1998, 2009), were
cultured in minimal essential medium (MEM) supplemented
with 10% heat-inactivated fetal bovine serum (hiFBS). HSC-
F cells (Akari et al., 1999) and a human T-cell line A2.01
(Folks et al., 1986) were cultured in RPMI1640 with 10%
hiFBS. A2.01 cells were negative for surface CD4 and CCR5
expression, and positive for surface CXCR4 expression (data
not shown). A2.01 cells stably expressing surface human- or
CyM-CD4, designated A2.01/HuCD4 and A2.01/CyMCD4,
respectively, were generated as follows. A2.01 cells were
transfected with H9-CD4+pCEP4 or HSCF-CD4+pCEP4
by using Amaxa Cell Line Nucleofector kit V (Lonza Ltd.)
and Nucleofector II device (Lonza Ltd.). Cells proliferated
in the presence of 400 µg/mL hygromycin B (Sigma-
Aldrich Co. LLC.) were pooled, and used for infection
experiments.
Virus Preparation and Reverse
Transcriptase (RT) Assay
Virus stocks were prepared from 293T cells transfected with
proviral clones by calcium phosphate co-precipitation method
(Adachi et al., 1986) or lipofectamine 2000 (Thermo Fisher
Scientific Inc.). Virion-associated RT activity was measured as
previously described (Willey et al., 1988; Nomaguchi et al.,
2013b).
Multi-Cycle Infection Assay
Equal RT units (2 × 106) of virus stocks were inoculated
into HSC-F cells (2 × 105), and cells were cultured in the
presence of 50 units/mL of recombinant human interleukin-2
(IL-2) (Bio-Rad Laboratories Inc.) throughout the observation
period. A2.01/HuCD4 and A2.01/CyMCD4 cells (1 × 105)
were infected with equal RT units (2 × 105 and 1 × 106,
respectively), and cultured in the presence of 400 µg/mL
hygromycin B throughout the observation period. Virus
replication was monitored by RT activity released into the culture
supernatants.
Single-Cycle Infection, Entry Kinetics
Assay, and Neutralization Assay
TZM-bl cells were seeded onto a well of a 96-well plate (4× 103),
and on the next day, equal RT units (2× 103 ∼ 1× 104) were
inoculated into cells. Amounts of input viruses were determined
by titration in TZM-bl cells to ensure that a virus sample,
conferring the highest luciferase activity among all samples used
in each experiment, produces a relative light unit (RLU) within
an appropriate range (1× 106 ∼ 8× 106 RLU). On day 2 post-
infection, cells were lysed with 1 × cell culture lysis buffer
(Promega Corporation), and were subjected to luciferase assays
according to the manufacturer’s instruction. Entry kinetics assay
was performed similarly as described previously (Brandenberg
et al., 2015). Briefly, virus samples were spin-inoculated into
TZM-bl cells at 10◦C for 1 hr to ensure virus attachment
without entry into cells. Virus-containing media were then
replaced with pre-warmed (37◦C) fresh media to start virus entry
process. At designated time intervals post-inoculation (from
0 to 120 min), a CXCR4 antagonist, AMD3100, was added
to culture media at a final concentration of 1 µM to stop
further viral entry. On day 2 post-infection, luciferase assays
were performed. Entry kinetics were assessed by calculating
RLU yielded at each time point post-infection relative to that
yielded at 120 min post-infection. To monitor neutralization
sensitivity for sCD4 and NAbs, virus samples were pre-
incubated with serial twofold dilutions of the reagents at 37◦C
for 1 h, and were inoculated into TZM-bl cells. Luciferase
assays were performed using cell lysates prepared on day 2
post-infection. Neutralization sensitivity was determined by
calculating RLU yielded in an appropriate reagent concentration
relative to that yielded without the reagent. Reagents used for
neutralization assays were as follows, and all anti-HIV-1 gp120
antibodies were obtained from NIH AIDS Reagent Program:
sCD4 Human (catalog no. CYT-304; ProSpec-Tany Technogene
Ltd.); IgG1 b12 (catalog no. 2640), NIH45-46 G54W (catalog
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no. 12174), 3BNC117 (catalog no. 12474), VRC01 (catalog no.
12033), and N6 (catalog no. 12968) antibodies that bind to
CD4bs; 17b antibody (catalog no. 4091) that recognizes CD4i;
CH01 mAb (catalog no. 12561), PG9 (catalog no. 12149),
and PGT145 (catalog no. 12703) antibodies that target V1/V2
structure.
Western Blot Analysis
To determine the expression level of Env proteins, lysates
of transfected cells and of virions from transfected cells
were prepared as described previously (Fujita et al., 2001,
2008). Lysates, normalized for their Gag-p24 amounts by the
HIV-1 p24 antigen ELISA kit (ZeptoMetrix Corporation),
were analyzed by western blotting using goat anti-HIV-1
rgp160 (MRC AIDS Directed Program Reagent Project,
catalog no. ADP409) and mouse anti-HIV-1 p24 (183-
H12-5C) (NIH AIDS Reagent Program, catalog no. 3537)
antibodies as previously described (Nomaguchi et al.,
2014).
Flow Cytometry
To determine expression level of cell surface CD4, cells were
stained with FITC Mouse Anti-Human CD4 (catalog no.
550628; BD Biosciences) as previously described (Doi et al.,
2010; Nomaguchi et al., 2010), and were analyzed by BD
FACSVerse Flow Cytometer and BD FACSuite Software (BD
Biosciences).
Molecular Dynamics (MD) Simulations of
HIV-1 Env Ectodomain (gp120 and gp41
Ectodomain) With CD4
HIV-1 Env ectodomain bound with CD4 was constructed for
ScaVR and its mutant by homology modeling with Molecular
Operating Environment (MOE) (Chemical Computing Group).
The crystal structure of HIV-1 Env ectodomain (gp120 and gp41
ectodomain) with CD4 at a resolution of 3.7 Å (1 Å = 0.1 nm)
(PDB code: 5VN3) (Ozorowski et al., 2017) was used as a
modeling template. MD simulations were performed as described
previously (Alam et al., 2016; Hikichi et al., 2016; Yokoyama
et al., 2016). Briefly, the simulations were done with the pmemd
module in the AMBER 16 program package (AMBER 2016,
University of California, San Francisco) using the AMBER ff14SB
(Maier et al., 2015) and GLYCAM_06j-1 (Kirschner et al., 2008)
force field, and the TIP3P water model for simulations of
aqueous solutions (Jorgensen et al., 1983). A non-bonded cut-
off of 10 Å was used. Bond lengths involving hydrogen were
constrained with SHAKE, a constraint algorithm to satisfy a
Newtonian motion (Ryckaert et al., 1977), and the time for
all MD simulations was set to 2 fs. After heating calculations
for 20 ps until 310 K using the NVT ensemble, simulations
were executed using the NPT ensemble at 1 atm, at 310 K
and in 150 mM NaCl for 500 ns. Free energies of the
molecules in solution were calculated from independent all-
atom MD trajectories of last 5 ns (100 frames) after 500 ns
MD simulations using MMPBSA.py program (Miller et al., 2012)
in the AmberTools16 (AMBER 2016, University of California,
San Francisco).
RESULTS
Three Mutations Accumulated in env
During in vitro Adaptation Experiments
Are Able to Individually Increase Viral
Replication Potential, Whereas the Virus
That Simultaneously Carry the Three
Mutations Replicates Most Efficiently in
Both Macaque and Human Cells
A prototype HIV-1mt clone, ScaVR, was generated by replacing
cyclophilin A-binding loop within gag-capsid region and entire
vif gene of a human-tropic HIV-1NL4−3 with the corresponding
regions of SIVmacMA239 (Figure 1A) (Kamada et al., 2006).
By adapting ScaVR to replication in HSC-F cells followed by
molecular cloning of the adapted viruses emerged, we successfully
obtained a better-growing clone designated 5R (Figure 1).
Sequence analysis showed that 5R Env-gp120 contains two
amino acid alterations, T138I in V1 domain and F275L in C2
domain (HIV-1NL4−3 amino acid numbering from start site
M), compared to ScaVR (Figure 1) (Kamada et al., 2006).
Then, we carried out a next round of virus adaptation in HSC-
F cells using 5R, and another proviral clone 5RA with an
increased replication ability was finally generated (Nomaguchi
et al., 2013a). While several new mutations were noted in
the 5RA genome, the only amino acid change in Env-gp120
responsible for viral growth enhancement in HSC-F cells
was E427K within C4 domain (Nomaguchi et al., 2013a).
We therefore constructed MN4 clone that has above three
substitutions (T138I, F275L, and E427K) within distinct domains
(V1, C2, and C4, respectively) of Env-gp120 relative to ScaVR
Env-gp120 (identical sequence with HIV-1NL4−3 Env-gp120)
(Figure 1).
While we did not determine previously the effects of T138I
and F275L mutations on viral replication potential (Kamada
et al., 2006), we showed that the E427K mutation was ineffective
in a human cell line MT4/CCR5 (Nomaguchi et al., 2013a).
To fully assess the growth-enhancing and species-specific effects
conferred by the three mutations, various proviral clones and
cell lines were newly generated. We introduced single, double
and triple Env-gp120 mutations (T138I, F275L, and/or E427K)
into parental clone ScaVR, and constructed seven mutant
clones (ScaVR+138, ScaVR+275, ScaVR+427, ScaVR+138/275,
ScaVR+138/427, ScaVR+275/427, and ScaVR+138/275/427).
Cell lines that stably express human CD4 or CyM CD4 were
also generated for comparative replication study from a human
cell line A2.01, a CD4-negative variant of CEM T-cell line A3.01
(Folks et al., 1986). A2.01 cells were transfected with either
human CD4 or CyM CD4 expression vector, and were selected
for CD4 expression by hygromycin B. Resultant human and
macaque CD4-positive cells were designated A2.01/HuCD4 and
A2.01/CyMCD4, respectively (Figure 2).
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FIGURE 1 | Proviral clones used in this study. (A) Genomes of HIV-1NL4−3 and its derivative HIV-1mt clone (ScaVR). Sequences from HIV-1NL4−3 (GenBank
accession number AF324493) and SIVmacMA239 (GenBank accession number M33262) are shown by white and black boxes, respectively. Amino acid mutations
and their locations (Env domains in parentheses) in Env-gp120 of 5R and MN4 clones are indicated. CypA, cyclophilin A. (B) In vitro adaptation processes of
HIV-1mt clones in HSC-F cells. Details for prolonged cultures of HSC-F cells infected with ScaVR and 5R (Genbank accession number AB266485) have been
reported previously (Kamada et al., 2006; Nomaguchi et al., 2013a).
Input viruses for infection experiments here were prepared
from 293T cells transfected with ScaVR, ScaVR+138,
ScaVR+275, ScaVR+427, ScaVR+138/275, ScaVR+138/427,
ScaVR+275/427 or ScaVR+138/275/427, and were inoculated
into HSC-F, A2.01/HuCD4, and A2.01/CyMCD4 cells. In
HSC-F and A2.01/HuCD4 cells, replication-enhancing effects
of single, double, and triple mutations in Env-gp120 on viral
growth property were readily observed in most cases as shown
in Figure 2. While ScaVR+275 and parental ScaVR exhibited
similar replication kinetics, ScaVR+138 and ScaVR+427 grew
more efficiently than ScaVR. These results have demonstrated
the ability and inability of T138I/E427K and F275L mutations,
respectively, to clearly promote viral growth in both CyM
and human cell lines. Although we found no detectable effect
of E427K mutation in human MT4/CCR5 cells previously
(Nomaguchi et al., 2013a), this mutation did enhance viral
replication in human A2.01/HuCD4 cells used in this study
(Figure 2). This is likely to be due to different viral clones and cell
lines used in the two studies. In our previous study, viral clones
with an intrinsically high replication potential (5R and HIV-
1NL4−3) and a target cell line with ability to efficiently support
viral infection (MT4/CCR5) were dually used, and thus, it is
quite conceivable that we were unable to detect a small increase
in viral growth. A double mutant ScaVR+138/427 grew more
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FIGURE 2 | Growth kinetics of ScaVR and its Env-gp120 mutants. Viruses were prepared from 293T cells transfected with proviral clones indicated and inoculated
into HSC-F, A2.01/HuCD4, and A2.01/CyMCD4 cells as described in Section “Materials and Methods.” Virus replication was monitored by RT activity released into
culture supernatants. Representative data from at least two independent experiments are shown.
robustly than their corresponding single mutants ScaVR+138
and ScaVR+427, whereas ScaVR+138/275 and ScaVR+275/427
grew similarly with ScaVR+138 and ScaVR+427, respectively.
Consistent with the apparent lack of biological effect by F275L
mutation described above, a double mutant ScaVR+138/427
and a triple mutant ScaVR+138/275/427 grew similarly and
best. In A2.01/CyMCD4 cells, viral replication rates were overall
slower than those in the other two cell lines, and thus, virus
growth of several clones (ScaVR, ScaVR+138, ScaVR+275, and
ScaVR+138/275) was negligible during the observation period
(Figure 2). However, growth-enhancing effect of F275L mutation
was obvious, since ScaVR+275/427 grew certainly better than
ScaVR+427. Moreover, ScaVR+138/275/427 replicated more
efficiently in A2.01/CyMCD4 cells than all the other clones tested
in Figure 2.
The results shown in Figure 2 have indicated that three
mutations in Env-gp120 (T138I, E427K, and F275L) can increase
viral replication potential. We were interested in distinct
mutational effects observed in the three cell lines used. In this
regard, we analyzed the surface CD4 expression levels of the
cell lines by flow cytometry, since it has been frequently shown
that CD4 receptor density on target cells significantly affect
Env-mediated viral entry efficiency (Lee et al., 1999; Joseph
et al., 2014; Arrildt et al., 2015; Beauparlant et al., 2017). As
shown in Figure 3, HSC-F and A2.01/HuCD4 cells expressed a
considerably higher level of surface CD4 than negative controls.
Of note, surface CD4 level on A2.01/CyMCD4 cells was slightly
higher than that on parental A2.01 cells but significantly lower
relative to those on the other two cell lines (Figure 3). The
F275L-mediated viral growth enhancement of ScaVR+427 and
ScaVR+138/427 was observable in A2.01/CyMCD4 cells but not
in HSC-F and A2.01/HuCD4 cells (Figure 2). This could be
explained by the difference in surface CD4 expression levels on
these cell lines. HSC-F cells express a higher level of CyM CD4
than A2.01/CyMCD4 cells (Figure 3). Generally, HIV-1 clones
grow more poorly in cells with a low surface CD4 level than in
those with a high level. Thus, A2.01/CyMCD4 cells may relatively
slow viral replication rates, and may facilitate detection of a
subtle increase in viral replication potential rendered by F275L
mutation (see results in the A2.01/CyMCD4 panel in Figure 2).
In summary, the above described three adaptive mutations
individually and cooperatively promote viral replication, and the
virus carrying the triple mutations always replicates best both in
CyM and human cells.
Three Adaptive Mutations (T138I, F275L,
and E427K) Affect Interaction Between
Env-gp120 and CD4
Of the three adaptive mutations, E427K was located in the
β20-β21 hairpin which has been suggested to be important
for CD4-induced conformational changes (Herschhorn et al.,
2017). E427 residue is also located at a CD4 contact site in
CD4bs within C4 domain (Pancera et al., 2017). Since these Env
mutations enhance viral growth potential, we examined whether
the Env expression level in cells and virions differ between ScaVR
and its mutant ScaVR+138/275/427 which shows the highest
replication ability among the mutants (Figure 2). Cell and virion
lysates were prepared from 293T cells transfected with ScaVR or
ScaVR+138/275/427, and subjected to western blotting analysis.
As is clear in Figure 4A, the two clones were found to express
Env at a similar level both in cells and virions. To evaluate the
effect of the three adaptive mutations on viral entry process,
we first comparatively determined the TZM-bl infectivity of
ScaVR and its mutant ScaVR+138/275/427, showing the highest
replication ability among mutants (Figure 2). Viruses prepared
from 293T cells transfected with ScaVR or ScaVR+138/275/427
were inoculated into TZM-bl cells, and on day 2 post-
infection, viral infectivity as judged by luciferase assays was
monitored. As expected, viral infectivity of ScaVR+138/275/427
was approximately twofold higher than ScaVR (Figure 4B).
We next performed entry kinetics assays to assess viral entry
efficiency. Both virus clones exhibited almost the same entry
kinetics, strongly suggesting their similar entry efficiency after
CD4-binding (Figure 4C). It has been reported that primary
HIV-1 viruses can acquire sCD4 sensitivity during an in vitro
long-term culture, and suggested that increase in sensitivity to
sCD4 is resulted from the enhanced interaction of Env-gp120 and
CD4 (Pugach et al., 2004; Humes and Overbaugh, 2011; Arrildt
et al., 2015). We then carried out sCD4 sensitivity assays by pre-
incubating each virus sample (ScaVR and ScaVR+138/275/427)
with sCD4 and by measuring viral infectivity in TZM-bl cells.
As shown in Figure 4D, the sensitivity of ScaVR+138/275/427
to sCD4 was modestly increased, i.e., the infectivity was
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FIGURE 3 | Surface CD4 expression on the cell lines used in this study. Various cell lines were stained with FITC-labeled CD4 antibody, and were subjected to flow
cytometry analysis. Numbers in graphs indicate the mean fluorescence intensity of each sample. (A) Analysis of CD4-positive HSC-F cells. Negative control is shown
by black line. (B) Analysis of A2.01 cell line and its derivatives. Parental A2.01 (CD4-negative), A2.01/CyMCD4, and A2.01/HuCD4 cells are shown by black, blue,
and red lines, respectively.
modestly decreased, relative to that of ScaVR. These results
strongly suggest that the three adaptive mutations augment viral
infectivity through enhancement of viral entry process by altering
the Env-CD4 interaction.
Three Adaptive Mutations (T138I, F275L,
and E427K) Do Not Affect Viral Sensitivity
to Neutralization by CD4bs Antibodies,
While Increasing Viral Resistance to
Neutralization by CD4i and V1/V2
Antibodies
In vitro adaptation of primary HIV-1 isolates in human T-cell
lines and PBMCs has been reported to result in enhancement
of their sensitivity to sCD4 and several NAbs (Moore and
Ho, 1995; Wrin et al., 1995; Clapham and McKnight, 2002;
Pugach et al., 2004). It has been shown that mutations in
HIV-1 Env (A204E and G312V), emerged by adapting SHIV
in macaque cells, independently promote Env/macaque CD4-
mediated viral entry, and that these two mutations influence
the sensitivity of SHIVs carrying HIV-1 Env to NAbs (Boyd
et al., 2015). Moreover, changes in the sensitivity of HIV-1
strains to NAbs can be linked with alteration in Env trimer
conformation (Boyd et al., 2015). Since the three adaptive
mutations in this study (T138I, F275L, and E427K) are located
in distinct domains (V1, C2, and C4, respectively), and may
affect the Env-CD4 interaction as described above (Figure 4),
we examined whether the Env mutations change viral sensitivity
to various NAbs that target CD4bs [IgG1 b12 (b12), NIH45-
46 G54W (G54W), 3BNC117 (3BNC), VRC01, and N6], CD4i
(17b), and V1/V2 [CH01 mAb (CH01), PG9, and PGT145].
The CD4bs antibodies [b12, G54W, 3BNC, VRC01, and N6
(Burton et al., 1991; Wu et al., 2010; Diskin et al., 2011; Shingai
et al., 2013)] recognize conserved structure formed by Env-gp120
trimer (Benjelloun et al., 2012). The 17b antibody recognizes
discontinuous epitope induced by Env conformational changes
following CD4 binding, and neutralizes only lab-adapted strains
such as HIV-1NL4−3 (Thali et al., 1993). The PG9 and PGT145
antibodies target quaternary structure of V1/V2 in Env trimer,
and the CH01 antibody recognizes a complex conformation
epitope (Walker et al., 2009, 2011; Bonsignori et al., 2011).
We performed neutralization sensitivity assays as described
for sCD4-sensitivity assays (Figure 4C) using NAbs instead of
sCD4. Based on the result demonstrating enhanced sensitivity
of ScaVR+138/275/427 to sCD4 (Figure 4C), it was rational to
assume that the sensitivity to neutralization by CD4bs antibodies
may increase through more exposed CD4bs. However, as is
quite clear in Figure 5, the three adaptive mutations did not
significantly affect sensitivity of ScaVR+138/275/427 to CD4bs
antibodies. Although the three mutations appeared to influence
the sensitivity to N6 antibody, IC50 value difference between
ScaVR and ScaVR+138/275/427 was not significant (p = 0.078
by t-test). In contrast, ScaVR+138/275/427 clearly showed
enhanced viral resistance to CD4i (17b) and V1/V2 (CH01, PG9,
and PGT145) antibodies relative to ScaVR (Figure 5). Totally,
while ScaVR carrying HIV-1NL4−3 env gene was neutralized
easily by the CD4i and V1/V2 antibodies, the three adaptive
mutations in Env-gp120 allowed the virus to escape from
antibodies that recognize epitopes formed by Env trimer. This
result thus has suggested that a biologically significant change in
Env trimer conformation may be caused by the three mutations.
Above experimental data suggest that the three adaptive
mutations (T138I, F275L, and E427K) induced increase in
binding ability of Env to CD4. To address this issue, we
conducted in silico structural study. Complex model of an
Env ectodomain (gp120 and gp41 ectodomain) and a soluble
CD4 was constructed for ScaVR and ScaVR+138/275/427 Env
clones using the reported complex structure and subjected to
the MD simulations to obtain dynamic structures in solution
(see Materials and Methods). Subsequently, binding energies of
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FIGURE 4 | Comparative characterization of ScaVR and ScaVR+138/275/427 viruses. (A) Effect of triple mutations in Env on Env expression level. Lysates were
prepared from transfected 293T cells as indicated. Samples containing equal Gag-p24 amounts were analyzed by western blotting using anti-HIV rgp160 and
anti-HIV-1 p24 antibodies. Representative data from two independent experiment are shown. (B) Effect of triple mutations in Env on viral infectivity. Viruses prepared
from 293T cells transfected with indicated proviral clones were inoculated into TZM-bl cells. On day 2 post-infection, cells were lysed and used for luciferase assays.
Viral infectivity is presented as RLU of ScaVR+3 relative to that of ScaVR. Mean values with standard errors (SE) are shown (n = 6). (C) Effect of triple mutations in
Env on entry efficiency. Virus samples prepared from 293T cells transfected with indicated proviral clones were spin-inoculated into TZM-bl cells at 10◦C for 1 h, and
were then replaced with pre-warmed fresh media. At indicated time points, AMD3100 was added to culture media at final concentration of 1 µM. On day 2
post-infection, cells were lysed, and subjected to luciferase assays. Relative infectivity is presented by calculating RLU of each virus sample at the indicated time
point relative to that of each virus sample at 120 min post-infection. Mean values ± SE are shown (n = 4). (D) Effect of triple mutations in Env on sCD4 sensitivity.
Viruses were prepared from 293T cells transfected with proviral clones indicated, and were incubated with sCD4 at 37◦C for 1 h. Virus samples were then inoculated
into TZM-bl cells, and on day 2 post-infection, cell lysates were prepared for luciferase assays. Relative infectivity, obtained by calculating RLU of each virus sample
incubated with sCD4 relative to that of each virus sample incubated without sCD4, is presented. Mean values ± SE are shown (n = 6).
the complexes were calculated using ensembles derived from
MD (Miller et al., 2012). Notably, the study has predicted that
binding energy of the Env to CD4 in solution will increase
by the three adaptive mutations: 1Gs were −18.8 ± 7.88 and
−27.7± 8.78 kcal/mol for ScaVR and ScaVR+138/275/427 Env-
CD4 complexes, respectively (Figure 6). In conclusion, these
in silico structural data are consistent with the enhanced Env-
CD4 interaction experimentally observed for the triple mutant
(Figure 4).
DISCUSSION
In this study, we investigated three adaptive mutations in HIV-1
Env-gp120 (T138I, F275L, and E427K) for their functional and
structural characteristics. These mutations spontaneously arose
in adaptation processes in macaque cells of HIV-1mt clones
derived from HIV-1NL4−3. The mutations act against unfavorable
circumstances individually and cooperatively to augment viral
replication capacity, and the virus that simultaneously carries
the three adaptive mutations grew best among clones tested in
macaque and human cells (Figure 2). Env-sCD4 interference
and entry kinetics assays suggested that the mutations enhance
viral replication potential via increase in the interaction of
Env-CD4 (Figures 2, 4). These results were supported by
MD simulations that predicted increased binding energy of
ScaVR+138/275/427 Env to CD4 relative to that of ScaVR
Env (Figure 6). Neutralization sensitivity assays have revealed
that these mutations can increase resistance to neutralization
by CD4i and V1/V2 antibodies, suggesting the change of
overall Env-trimer conformation (Figure 5). These results may
imply that single-amino acid mutations within V1, C2, and
C4 domains cooperatively act on function and structure of
HIV-1 Env.
Frontiers in Microbiology | www.frontiersin.org 8 January 2019 | Volume 10 | Article 2
fmicb-10-00002 January 14, 2019 Time: 14:45 # 9
Doi et al. Analysis of Adaptive Mutations in HIV-1 Env-gp120
FIGURE 5 | Neutralization sensitivity assays for ScaVR and ScaVR+138/275/427 (ScaVR+3). Viruses were prepared from 293T cells transfected with indicated
proviral clones. Virus samples were pre-incubated with each NAb at 37◦C for 1 h, and were inoculated into TZM-bl cells. On day 2 post-infection, cells were lysed for
luciferase assays. Relative infectivities were calculated by RLU values with indicated concentrations of NAb relative to that without NAb, and then relative inhibition
rates (1.0 minus relative infectivity) were determined and are presented. IC50 values are indicated in the upper panel. Mean values ± SE are shown (n = 6 or more).
Representative graph data of neutralization sensitivity assays using NAbs are shown. b12, IgG1 b12; G54W, NIH45-46 G54W; 3BNC, 3BNC117; CH01, CH01 mAb.
We have selected and summarized several relevant studies
on HIV-1 adaptation process (Table 1). In vitro adaptation in
human T-cell lines and PBMCs of primary HIV-1 isolates appears
to commonly lead to increased affinity of their Env proteins
for sCD4 and several NAbs (Moore and Ho, 1995; Wrin et al.,
1995; Clapham and McKnight, 2002; Pugach et al., 2004). Several
SHIVs bearing env genes from transmitted/founder viruses or
HIV-1 primary isolates exhibit reduced ability to use macaque
CD4 as a receptor. Through adaptations in macaque cells or
individuals, SHIVs carrying such env genes gained a single-
amino acid mutation that enhances macaque CD4-mediated
entry (Humes and Overbaugh, 2011; Humes et al., 2012; Boyd
et al., 2015; Del Prete et al., 2017). However, Env mutations
that confer the ability to enhance macaque CD4 utilization were
not uniformly distributed among SHIVs (Table 1). Moreover,
while adaptive mutations (A204E and G312V) that had emerged
during in vitro adaptation changed neutralization properties, the
other mutation (A281T) that had been acquired during in vivo
adaptation did not significantly affect neutralization sensitivities
to NAbs tested (Boyd et al., 2015; Del Prete et al., 2017). This
could probably be due to difference of env genes and host
environments used for adaptation (Table 1). Neutralization-
sensitive viruses (HIV-1/SHIVs), which had become as such
during prolonged culture periods, were reported to re-acquire
neutralization-resistance through adaptation processes in an
experimentally infected macaque or an accidentally infected
human (Cheng-Mayer et al., 1999; Beaumont et al., 2001; Si et al.,
2001). In this study, we found that a neutralization-sensitive
HIV-1NL4−3 Env becomes resistant to NAbs’ neutralization by
acquiring the three adaptive mutations (T138I, F275L, and
E427K) during in vitro adaptation, albeit to a lesser degree
previously reported (Table 1).
Parental HIV-1mt clone, ScaVR, used in this study was
generated from HIV-1NL4−3 as a backbone (Kamada et al.,
2006). HIV-1NL4−3 is categorized into a ‘tier 1’ virus that
displays high sensitivity to antibody-mediated neutralization
(Munro et al., 2014). A recent study reported that CD4i
antibody, 17b, is accessible to some tier 1 Env proteins
tested prior to their structural rearrangement induced by CD4
engagement (Boliar et al., 2018). Env on surface of HIV-1NL4−3
virions frequently adopts CD4-induced conformation. This can
explain the increased sensitivity of HIV-1NL4−3 Env to 17b’s
neutralization (Munro et al., 2014). Also, in agreement with the
results of this study (Figure 5), PG9 and PGT145 antibodies
that recognize V1/V2 quaternary epitope has been shown to
potently neutralize HIV-1NL4−3 (Walker et al., 2009, 2011).
Because the three adaptive mutations (T138I, F275, and E427K
in V1, C2, and C4 domains, respectively) increased resistance
to neutralization by CD4i and V1/V2 antibodies (Figure 5), we
speculated that the structural adaptation of Env for increasing
affinity for CD4 had simultaneously altered structural property
around some Env epitopes. For example, E427K substitution
alters the electric charge around the bridging sheet and therefore
might alter the molecular interaction with the CD4i antibody.
T138I substitution alters hydrophobicity of the V1/V2 portion
and therefore might influence the interactions with the V1/V2
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FIGURE 6 | Three-dimensional locations of Env-gp120 mutations in the MD-derived Env ectodomain (gp120 and gp41 ectodomain) bound with soluble CD4. HIV-1
Env ectodomain bound with CD4 was constructed for ScaVR and ScaVR+138/275/427 clones by the homology modeling method using the crystal structure of
HIV-1 Env ectodomain with CD4 (PDB code: 5VN3) (Ozorowski et al., 2017). The models were subjected to MD simulations for 500 ns to obtain dynamic structures
in solution (see Materials and Methods). Binding energies of the Env proteins to CD4 molecule were calculated using ensembles derived from last 5 ns after 500 ns
MD simulations using MMPBSA.py program (Miller et al., 2012) in the AmberTools16 (AMBER 16, University of California, San Francisco). The Env-CD4 complex
structure of ScaVR at 100 ns of MD simulation is shown with binding energies of ScaVR and ScaVR+138/275/427 Env proteins to CD4.
antibodies. On the other hand, the three substitutions did not
alter viral susceptibility to CD4bs antibodies, indicating that
the Env contact sites of the CD4 and CD4bs antibodies are
different and that structural properties of the latter were not
significantly influenced by the three mutations. Whatever the
structural changes are, our study clearly shows that the structural
adaptation of Env for increasing viral growth ability under no
selective pressures of antibodies does not always result in increase
in viral susceptibility to Env antibodies. Molecular understanding
of such evolutionary pathways may provide a basis to develop
HIV-1 that effectively grows in monkeys.
Env proteins from macrophage-tropic viruses, which can
efficiently use CD4 receptor at a lower density, were highly
sensitive to sCD4 neutralization compared with those from
subject-matched T cell-tropic viruses. This finding indicates that
increase in sCD4 sensitivity may imply enhanced interaction of
Env-gp120 and CD4 (Arrildt et al., 2015), and can be accounted
for by (1) more exposed CD4bs (probably leading to increased
sensitivity to CD4bs antibodies), (2) tendency to adopt CD4-
induced conformation, or (3) increase in affinity for CD4 (Yen
et al., 2014; Arrildt et al., 2015). ScaVR+138/275/427, which
has three mutations in the env gene from HIV-1NL4−3, did
not significantly increase sensitivity to five CD4bs antibodies
tested relative to parental ScaVR (Figure 5). Although we
cannot definitely conclude that the observed sensitivity of
ScaVR+138/275/427 to the CD4bs antibodies is unrelated to
the small increase in its sensitivity to sCD4 neutralization, it
is unlikely that the three mutations cause further exposure of
CD4bs on the tier 1 HIV-1NL4−3 Env. The triple mutations were
also found to enhance resistance of the HIV-1NL4−3 Env to a
CD4i antibody (Figure 5), which indicates no further shift from
its original state (intrinsically highly sensitive state) toward a
CD4-induced conformation. Additionally, the entry kinetics of
ScaVR+138/275/427 was similar to those of ScaVR, suggesting
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the three mutations are unlikely to enhance the entry process after
CD4-binding (Figure 4B). Furthermore, our MD simulations
predict that the three mutations would increase binding affinity
of the Env for CD4 in solution (Figure 6). The data are consistent
with the reported results that E427 is located at a CD4 contact
site in the β20-β21 loop and that T138I is located in the V1
region that supports binding of CD4 (Yokoyama et al., 2016). In
total, the increase in sCD4 sensitivity in the Env triple mutant
(ScaVR+1385/275/427) is highly likely to be associated with its
enhanced affinity for CD4.
Analyses on spontaneous and biologically relevant mutations
found in adaptation studies contribute to the identification of
mutable sites, where HIV-1 viruses change viral replication
potential and NAb sensitivity but maintain their viability. The
search and identification of such mutable sites is important
as well as determination of epitopes targeted by NAbs, escape
mutations from host immune response, and anti-viral drug
resistance mutations, etc. Moreover, analysis of changes in
function and structure of viral proteins by adaptive mutations
serves to establish new way to control viral replication: taking the
adaptation ability of viruses to host environments into accounts
to act against viruses.
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